The FDA has approved Brinsupri (brensocatib) to treat non-cystic fibrosis bronchiectasis (NCFB), a chronic inflammatory lung condition, in patients ages 12 years and older.

NCFB is a progressive respiratory condition. Patients experience frequent cough, shortness of breath, and recurrent infections due to the damage the disease causes to the lungs. Unlike other respiratory diseases that are characterized by airway narrowing, bronchiectasis causes airways to permanently widen, making it harder to clear mucus and bacteria, leading to persistent inflammation and infection. About 500,000 people in the United States are diagnosed with the condition.

“For the first time, we have a treatment that directly targets neutrophilic inflammation and addresses a root cause of bronchiectasis exacerbatio

See Full Page